In Vitro Diagnostics
In Vitro Diagnostic (IVD) devices encompass a wide range of applications such as molecular diagnostics, immunoassays, Remote Patient Monitoring (RPM) and point-of-care (POC) testing. These diagnostic tools are integral to our mission, enabling healthcare providers to detect and monitor diseases like cancer, infectious diseases, and genetic disorders with precision and reliability.
New IVD developers face technical challenges such as ensuring high sensitivity and specificity, achieving rapid turnaround times, and maintaining cost-effectiveness for widespread adoption. Additionally, the integration of advanced technologies such as novel sensors, next-generation sequencing and digital PCR presents opportunities and complexities in equal measure. Regulatory compliance and navigating the evolving landscape of global health standards are also critical.
Emerging trends such as personalised medicine and the increasing demand for home-based testing solutions are reshaping the IVD market. Meanwhile, the rise of connected diagnostics, which leverage data analytics and cloud computing, holds promise for more proactive and informed healthcare decisions, despite the barriers raised by data security and interoperability.
How Perdigó can help?
Perdigó offers deep technological and MedTech. product development expertise to innovators in the field of IVD. High calibre engineering is required to design accurate and reliable devices that integrate the latest technologies in microfluidics, automation, and sensorics.
By embedding usability engineering into the development from the beginning, we ensure new IVD products are intuitive and efficient for the end user, meeting the demands of busy clinical and laboratory environments.
Every IVD device is meticulously prepared for clinical validation, regulatory submission, and a swift market launch with rigorous project, risk and quality management.
See what people say about us
“Perdigó’s risk management work, engineering documentation and expert advice have supported the succesful regulatory submission and approval of the Airway Shield device.”
Julio M. Alonso, CEO and Chief Medical Offer
“Perdigó’s showed great commitment to deliver groundbreaking technology in the field of IVF, demostrating deep engineering and medical device expertise.”
Ana García Poyo, VP Op. and Chief Industrial Officer
“Perdigó’s risk management work, engineering documentation and expert advice have supported the succesful regulatory submission and approval of the Airway Shield device.”
Julio M. Alonso, CEO and Chief Medical Offer
“Perdigó’s showed great commitment to deliver groundbreaking technology in the field of IVF, demostrating deep engineering and medical device expertise.”
Ana García Poyo, VP Op. and Chief Industrial Officer
The Blue Box have built a pain-free, low-cost, sensitive, radiation-free device to detect breast cancer in urine with a sensitivity of 88.33%.
The IVF (In Vitro Fertilization) market encompasses a range of technologies integrated into devices designed to enhance the efficiency, accuracy, and success rates of fertility treatments.
Perdigó has supported the development of many medical devices, ranging from seemingly simple hospital accessories to advanced electrostimulation system, and including mechanical dose counters to be manufactured in millons of units per annum.
Perdigó has extensive experience in the development of drug delivery devices for different routes of administration, including inhalation (soft mist and dry powder), parenteral, and ophthalmic.
In Vitro Diagnostic (IVD) devices encompass a wide range of applications such as molecular diagnostics, immunoassays, Remote Patient Monitoring (RPM) and point-of-care (POC) testing.
Remote dental monitoring
Smiletornix’s initial idea was a hardware device for capturing images of the patients’s gums and teeth, powered by an AI model running in the cloud to perform diagnosis. Through exhaustive collaboration, Perdigó was challenged to conceptualize Smiletronix’s first device.
Cell Therapy System
Cell therapy is at the forefront of medical innovation, offering new hope for treating diseases such as cancer, autoimmune disorders, and genetic conditions.
Dialysis biosensor
Chronic kidney disease (CKD) affects 10% of the global adult population. It is a growing public health concern due to rising rates of these underlying conditions and the aging population.
User-centric connectivity
Wayra is an innovative connectivity platform that simplifies the integration of connected medical devices into daily life. Using NFC technology, it enables effortless data synchronization with just a “tap,” eliminating the need for additional apps.